---
title: Yellowbrick Provides Free Access to Its Cloud Data Warehouse for COVID-19
  Vaccine Research
author: Yellowbrick
description: Yellowbrick data provides free access to its award-winning cloud
  data warehouse for COVID-19 vaccine research.
date: 2020-04-16
coverImage: /uploads/Yellowbrick_NewsImage11.jpg
boilerplate: Yellowbrick Data provides the world’s only modern data warehouse
  for hybrid and multi-cloud environments. Enterprises rely on Yellowbrick Data
  Warehouse to power critical business outcomes and get answers to the hardest
  business questions for improved profitability, better customer loyalty, and
  faster innovation in near real time, and at a fraction of the cost of
  alternatives. Yellowbrick offers superior price/performance for thousands of
  concurrent users on petabytes of data, along with the unique ability to run
  analytic workloads on premises, in a private cloud, and/or in any public cloud
  and manage them in a simple, consistent way—all with predictable pricing via
  fixed-cost annual subscription.
featured: false
---
PALO ALTO, Calif. – April 16, 2020 – Yellowbrick announced that it is providing free access to its cloud data warehouse, a powerful analytics processing technology, to give researchers and companies actively working on a vaccine for the novel coronavirus (COVID-19) real-time access and insights to critical data.  

“We’re proud to offer access to Yellowbrick’s analytics capabilities to researchers who are working tirelessly to make a difference,” said Neil Carson, CEO, Yellowbrick. “We think our innovative technology can give them a powerful boost and help speed the time to insight.”

[Virtusa](https://www.virtusa.com/), a digital strategy and services company, has partnered with Yellowbrick to provide implementation consulting and access for its Life Sciences platform, vLife™. Companies actively working on vaccines will have the ability to connect data from a broad range of clinical, drug development and media sources generating large of amounts of daily data into an analytic platform designed for delivering time-critical insights.   

“By joining the capabilities of Virtusa and Yellowbrick, we can help customers provide real-time ingestion, faster performance, and powerful analytics,” said Anthony Lange, SVP, Healthcare & Life Science, Virtusa. “Synthetic data sets available in [vLife™](https://www.virtusa.com/solution/vlife/) significantly accelerate research and clinical trials to reduce the timeline for finding and delivering life saving drug therapies.”

“We’re pleased to be joined by Virtusa in the effort to support life-saving work,” said Neil Carson. “It’s essential that companies join forces to support COVID-19 research and trials and we are thrilled to partner and bring together our powerful analytics engine with Virtusa’s vLife™ platform.” 

Researchers actively working on a COVID-19 vaccine can find more information at [yellowbrick.com/covid19/](https://www.yellowbrick.com/).